Finance entity

Mereo BioPharma Group plc

Company MREO

markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Fermi Inc., the most common co-covered peer. Each story carries 4 original sources on average, compared with 2.9 for the broader beat in this window.

Last mentioned: Mar 5, 2026

Entity pulse

Recent coverage · Mereo BioPharma Group plc

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Mereo BioPharma Group plc

markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Fermi Inc., the most common co-covered peer. Each story carries 4 original sources on average, compared with 2.9 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 6.2. We currently track 1 Finance story that mention Mereo BioPharma Group plc, all published on March 5, 2026.

Stories tracked
1
Sources per story
4

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 98 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Mereo BioPharma Group plc. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Discovery Phase Begins

    Courts likely to rule on motions to dismiss, leading to the exchange of internal corporate documents.

  2. Lead Plaintiff Deadline (Estimated)

    Expected window for investors to file motions to lead the class actions against RARE, MREO, and NAVAN.

  3. Coordinated Legal Alerts

    Pomerantz Law Firm issues a series of reminders for class action deadlines across four major firms.

Stories mentioning Mereo BioPharma Group plc 1

Markets Neutral

Pomerantz Law Firm Issues Securities Class Action Deadlines for Four Firms

Pomerantz Law Firm has issued urgent reminders for investors regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These legal actions target alleged securities fraud and disclosure failures, setting critical deadlines for lead plaintiff applications.

4 sources

Mereo BioPharma Group plc is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.